STML - Stemline Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $11.3. This is a potential upside of $11.3 (0%) from yesterday's end of day stock price of $0.

Stemline Therapeutics's activity chart (see below) currently has 42 price targets and 41 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 11.79% with an average time for these price targets to be met of 101.43 days.

Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 05-May-2020. First documented stock forecast 29-Aug-2013.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 06-Jun-2016

$12.5

$0.67 (5.66%)

5 years 9 months ago
(05-May-2020)

0/4 (0%)

$0.41 (3.39%)

Buy Since 17-Mar-2015

$11

$-0.83 (-7.02%)

5 years 9 months 1 days ago
(04-May-2020)

1/5 (20%)

$-1.11 (-9.17%)

623

Hold Since 04-May-2020

$10

5 years 9 months 1 days ago
(04-May-2020)

1/2 (50%)

$5.6 (127.27%)

38

Buy Since 06-Aug-2019

$9

$-2.83 (-23.92%)

$25

5 years 10 months 20 days ago
(16-Mar-2020)

1/8 (12.5%)

$4.94 (121.67%)

49

$23

$11.17 (94.42%)

$23

9 years 2 days ago
(03-Feb-2017)

0/4 (0%)

$16.45 (251.15%)

Show more analysts

Please expand the browser size to see the chart

What is STML (Stemline Therapeutics) average time for price targets to be met?

On average it took 101.43 days on average for the stock forecasts to be realized with a an average price target met ratio 11.79

Which analyst has the current highest performing score on STML (Stemline Therapeutics) with a proven track record?

DAVID NIERENGARTEN

Which analyst has the current lower performing score on STML (Stemline Therapeutics) with a proven track record?

JOSEPH PANTGINIS

Which analyst has the most public recommendations on STML (Stemline Therapeutics)?

David Nierengarten works at WEDBUSH and has 8 price targets and 5 ratings on STML

Which analyst is the currently most bullish on STML (Stemline Therapeutics)?

Joseph Pantginis with highest potential upside - $20.17

Which analyst is the currently most reserved on STML (Stemline Therapeutics)?

Joseph Catanzaro with lowest potential downside - -$2.83

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?